Delayed haemolysis after IV artesunate therapy for P. falciparum infection

O'Connor, Ròisìn; Conlan, Ciara; Grant, Conor; Kinsella, Nora; Moriarty, Miriam; Carr, Bernard; Melanophy, Gail; Doyle, Caitriona; Merry, Concepta; Bannan, Ciarán; Bergin, Colm

doi:10.1016/j.tmaid.2021.102230

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Adverse drug reactions observed with artesunate include post-treatment hemolysis and have been described in previous reports and studies. [2][3][4][5][6][7][8] Although the exact incidence of delayed hemolysis with parenteral artesunate is unknown, studies have detected it in approximately 20% of treated patients. 3,4,9 The proposed mechanism behind delayed hemolysis is linked to a class effect of the artemisinin medications.…”

Section: Introductionmentioning

confidence: 99%

Delayed Hemolysis With Parenteral Artesunate

2022

View full text Add to dashboard Cite

Artesunate is an effective and first-line therapy option in patients with severe malaria caused by Plasmodium species. Among adverse effects of the drug is a phenomenon of delayed hemolysis. This usually occurs at least 7 days after initiation of therapy, and is characterized by reductions in hemoglobin and haptoglobin and an increase in lactate dehydrogenase. Here, we report an instance of delayed hemolysis in a patient probably attributed to parenteral artesunate therapy.

show abstract